CIDP Prevalence, Disease Burden, and Clinical Challenges

Welcome back to another NeurologyLive Peer Exchange series. The panel opens with a discussion of CIDP prevalence, noting that estimates vary depending on the diagnostic criteria used. A strict case definition from a New South Wales population study places prevalence at approximately 1 per 100,000, while a more clinically based study from Olmsted County suggests a higher figure of around 1 in 10,000. One expert contextualizes this further, estimating that roughly 40,000–50,000 patients in the U.S. are affected, and that CIDP accounts for approximately 20% of patients presenting to peripheral neuropathy centers with initially unrecognized neuropathy. The panel characterizes CIDP as rare but not ultra-rare.

Regarding disease burden, panelists highlight the variability of the clinical presentation. Some patients experience severe disability, with one study suggesting approximately 50% are wheelchair-dependent at some point, while others present more insidiously with balance impairment and fall risk. Core symptoms include proximal and distal weakness, sensory loss, and difficulties with ambulation and hand function, with pain and fatigue also commonly reported.

The discussion then turns to diagnostic challenges. Panelists emphasize that CIDP remains a clinical diagnosis without a reliable biomarker or imaging standard. Key clinical clues include proximal weakness, global areflexia, and gait ataxia, but nerve conduction studies can be difficult to interpret due to secondary axonal loss obscuring the underlying demyelinating pattern. CIDP variants further complicate early diagnosis. Panelists also note that patients with residual deficits from Guillain-Barré syndrome are frequently misdiagnosed with CIDP, contributing to both overdiagnosis and underdiagnosis, and that diagnostic delays remain a significant concern.

In the next episode, "Navigating CIDP Guidelines, Misdiagnosis, and Disease Variants," panelists continue their discussion on CIDP and highlight the limited real-world adoption of the 2021 diagnostic guidelines, the concept of monophasic CIDP, and the unique diagnostic and treatment challenges posed by CIDP variants including distal, sensory, motor, focal, and multifocal forms.